Journals / Türk Nöroşirürji Dergsi / 2002 / Cilt: 12 - Sayı: 3

Management of spasticity with spinal origin by intrathecal baclofen treatment, Report of three cases

İntratekal baklofen tedavisi ile spinal orijinli spastisite kontolü, 3 olgu sunumu

Pages
229–235
Publication Date
2022-11-04
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

The pump used in the study has been assessed as having disadvantages in terms of risk of infection, dose regulation and treatment efficiency.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: To share our experiences with colleagues that gained from three patients in whom a intrathecal baclofen pump has been applied because of spasticity with spinal origin since 1995.
📊
Key Findings & Data:Methods: Manual intrathecal drug pumps have been applied to three patients having total spinal cord lesion and followed for average 46 months.
💡
Conclusion & Impact:The pump used in the study has been assessed as having disadvantages in terms of risk of infection, dose regulation and treatment efficiency.
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objective: To share our experiences with colleagues that gained from three patients in whom a intrathecal baclofen pump has been applied because of spasticity with spinal origin since 1995. Methods: Manual intrathecal drug pumps have been applied to three patients having total spinal cord lesion and followed for average 46 months. Medical records of the patients have been reviewed retrospectively. Results: Spasticity with spinal origin, which had not been controlled with oral baclofen treatment before, in patient one and two has been controlled for 66 months and 62 months respectively until the pumps were removed because of infection. Dose regulation has been continuing in the last patient with total cervical spinal cord lesion. Conclusions: In case of spasticity control, intrathecal administered baclofen has significant superiorities when compared with oral baclofen. The pump used in the study has been assessed as having disadvantages in terms of risk of infection, dose regulation and treatment efficiency.

Özet

Amaç: 1995 yılından beri spinal orijinli spastisite nedeniyle, departmanımızda İntratekal baklofen pompası uygulanan 3 olgudan elde edilen tecrübelerimizi meslektaşlarımız ile paylaşmak. Yöntemler: Total spinal kord lezyonu bulunan ve literatür verilerine göre İntratekal baklofen uygulama endikasyonlarına uyan 3 olguya manuel İntratekal ilaç pompası takılmış ve olgular ortalama 46 ay takip edilmiştir. Olguların tıbbi kayıtları retrospektif olarak incelenmiştir. Bulgular: Olgulardan birincisinde 66 ay, ikincisinde 62 ay sonra, infeksiyon nedeni ile pompa çıkarılmak zorunda kalınana kadar, daha evel oral ilaçlar ile kontrol altına alınamayan spinal orijinli spastisite, komplikasyonsuz olarak kontrol altında tutulmuştur. Diğer servikal total spinal kord lezyonlu olguda ise halen doz ayarlama çalışmaları devam etmektedir. Sonuç: İntratekal kullanılan baklofen spastisite konusunda, oral kullanılan baklofene göre belirgin üstünlüklere sahiptir. Kullanılan manuel pompa, literatürde tanımlanan programlanabilir pompalara göre infeksiyon riski, doz ayarlaması ve tedavi etkinliği yönünden dezavantajlı bulunmuştur.

🔖

Cite This Article

AKAY, K. M., İZCİ, Y., KAHRAMAN, S., TİMURKAYNAK, E. (2022). Management of spasticity with spinal origin by intrathecal baclofen treatment, Report of three cases. Türk Nöroşirürji Dergsi, Cilt: 12 - Sayı: 3, 229–235. https://ajindex.com/articles/637440

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (1)

  1. Akman MN, Loubser PG, Donovan WH, O'Neill ME, Rossi CD: Intrathecal baclofen: does tolerance occur? Paraplegia 31: 516-520,1993 2. Albright AL: Neurosurgical treatment of spasticity: selective posterior rhizotomy and intrathecal baclofen. Stereotact Funct Neurosurg 58:3-13,1992 3. Al-Khodairy AT, Vuagnat H, Uebelhart D: Symptoms of recurrent intrathecal baclofen withdrawal resulting from drug delivery failure: a case report. Am J Phys Med Rehabil 78:272-277,1999 4. Azouvi P, Mane M, Thiebaut JB, Denys P, Remy-Neris O, Bussel B: Intrathecal baclofen administration for control of severe spinal spasticity: functional improvement and long-term follow-up. Arch Phys Med Rehabil 77:35-39,1996 5. Becker R, Sure U, Petermeyer M, Bertalanffy H: Continuous intrathecal baclofen infusion alleviates autonomic dysfunction in patients with severe supraspinal spasticity. J Neurol Neurosurg Psychiatry 66:114, 1999 6. Broseta J, Morales F, Garcia-March G, Sanchez- Ledesma MJ, Anaya J, Gonzalez-Darder J, Barbera J: Use of intrathecal baclofen administered by programmable infusion pumps in resistent spasticity. Acta Neurochir Suppl (Wien) 46:39-45,1989 7. Broseta J, Garcia-March G, Sanchez-Ledesma MJ, Anaya J, Silva I: Chronic intrathecal baclofen administration in severe spasticity. Stereotact Funct Neurosurg 55:147-153, 1990 8. Bushman W, Steers WD, Meythaler JM: Voiding dysfunction in patients with spastic paraplegia: urodynamic evaluation and response to continuous intrathecal baclofen. Neurourol Urodyn 12:163-170, 1993 9. Coffey RJ, Cahili D, Steers W, Park TS, Ordia J, Meythaler J, Herman R, Shetter AG, Levy R, Gill B, Smith R, Wilberger J, Loeser JD, Chabal C, Feler C, Robertson JT, Penn RD, Clarke A, Burchiel KJ, Leibrock LG: Intrathecal baclofen for intractable spasticity of spinal origin: Results of a long term multicenter study. J Neurosurg 78: 226-232,1993 10. Delhaas EM, Brouwers JR: Intrathecal baclofen overdose: report of 7 events in 5 patients and review of the literature. Int J Clin Pharmacol Ther Toxicol 29:274-280, 1991 11. Dressnandt J, Conrad B: Lasting reduction of severe spasticity after ending chronic treatment with intrathecal baclofen. J Neurol Neurosurg Psychiatry 60: 168-173, 1996 12. Galloway A, Falope FZ: Pseudomonas aeruginosa infection in an intrathecal baclofen pump: successful treatment with adjunct intra-reservoir gentamicin. Spinal Cord 38: 126-128, 2000 13. Gardner B, Jamous A, Teddy P, Bergstrom E, Wang D, Ravichandran G, Sutton R, Urqu